(E)-3-(4-((E)-2-(2-Chloro-4-Fluorophenyl)-1-(1H-Indazol-5-Yl)But-1-En-1-Yl)Phenyl)Acrylic Acid (E)-3-(4-((E)-2-(2-氯-4-氟苯基)-1-(1H-吲唑-5-基)丁-1-烯-1-基)苯基)丙烯酸
CAS 1365888-06-7 MFCD465888067
化学结构图
SMILES: CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl
化学属性
| Mol. Weight | 446.9064 |
|---|---|
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | (E)-3-(4-((E)-2-(2-Chloro-4-Fluorophenyl)-1-(1H-Indazol-5-Yl)But-1-En-1-Yl)Phenyl)Acrylic Acid |
|---|---|
| Formula | C26H20ClFN2O2 |
| Synonym | GDC0810; GDC 0810; GDC-0810; ARN810; ARN 810; ARN-810; RG6046; RG-6046; RG 6046; Brilanestrant |
| IUPAC Name | (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| InChIKey | BURHGPHDEVGCEZ-KJGLQBJMSA-N |
| InChI | InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)/b12-5+,26-21+ |
| Canonical SMILES | O=C(O)/C=C/C1=CC=C(C=C1)/C(C2=CC3=C(NN=C3)C=C2)=C(CC)\C4=CC=C(C=C4Cl)F |
| Chemical Name Translation | (E)-3-(4-((E)-2-(2-氯-4-氟苯基)-1-(1H-吲唑-5-基)丁-1-烯-1-基)苯基)丙烯酸 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- Brilanestrant, also known as GDC-0810, ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. GDC-0810 functions by binding to the estrogen receptor, inducing a conformational change resulting in the degradation of the receptor. GDC-0810 or ARN-810 demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.
京ICP备2020036287号